电话:
400-7060-959
传真:
+86 10 56315212-8813
电子邮件:
orders@antibodies-online.cn

Coiled-Coil Domain Containing 88C (CCDC88C) (AA 1450-1500) 抗体

CCDC88C 适用: 人 IP 宿主: 兔 Polyclonal unconjugated
产品编号 ABIN7452244
发货至: 中国
  • 抗原 See all Coiled-Coil Domain Containing 88C (CCDC88C) 抗体
    Coiled-Coil Domain Containing 88C (CCDC88C)
    抗原表位
    AA 1450-1500
    适用
    • 3
    • 1
    • 1
    宿主
    • 3
    克隆类型
    • 3
    多克隆
    标记
    • 3
    非结合性
    应用范围
    • 1
    • 1
    • 1
    Immunoprecipitation (IP)
    原理
    Rabbit anti-Daple Antibody, Affinity Purified
    纯化方法
    Affinity Purified
    免疫原
    between AA 1450 and 1500
    亚型
    IgG
    Top Product
    Discover our top product CCDC88C Primary Antibody
  • 应用备注

    IP: 2 - 5 μg/mg lysate

    WB: Not recommended. ABIN7452244 has not performed satisfactorily when used for WB of Daple in crude preparations (e.g. whole cell lysate). This antibody can be used for WB of enriched (e.g. immunoprecipitated) sources of Daple.

    限制
    仅限研究用
  • 浓度
    1000 μg/mL
    缓冲液
    Tris-citrate/phosphate buffer, pH 7 to 8 containing 0.09 % Sodium Azide
    储存液
    Sodium azide
    注意事项
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    储存条件
    4 °C
    有效期
    12 months
  • 抗原
    Coiled-Coil Domain Containing 88C (CCDC88C)
    别名
    Daple (CCDC88C 产品)
    别名
    0610010D24Rik antibody, AV000935 antibody, AW324073 antibody, Daple antibody, mKIAA1509 antibody, RGD1307429 antibody, DAPLE antibody, HKRP2 antibody, KIAA1509 antibody, MGC160122 antibody, coiled-coil domain containing 88C antibody, Ccdc88c antibody, CCDC88C antibody
    背景
    Background: Daple (Dvl-associating protein with a high frequency of leucine residues) is a negative regulator of the canonical Wnt signaling pathway and acts downstream of DVL to inhibit CTNNB1/Beta-catenin stabilization [taken from the Universal Protein Resource (UniProt) Q9P219].
    基因ID
    440193
    NCBI登录号
    NP_001073883
    UniProt
    Q9P219
You are here: